Search for other papers by Carla Scaroni in
Google Scholar
PubMed
Search for other papers by Nora M Albiger in
Google Scholar
PubMed
Search for other papers by Serena Palmieri in
Google Scholar
PubMed
Search for other papers by Davide Iacuaniello in
Google Scholar
PubMed
Search for other papers by Chiara Graziadio in
Google Scholar
PubMed
Search for other papers by Luca Damiani in
Google Scholar
PubMed
Search for other papers by Marialuisa Zilio in
Google Scholar
PubMed
Search for other papers by Antonio Stigliano in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by Rosario Pivonello in
Google Scholar
PubMed
Search for other papers by the Altogether to Beat Cushing’s Syndrome (ABC) study group in
Google Scholar
PubMed
ACS, adrenal Cushing’s syndrome; CD, Cushing’s disease; CS, Cushing’s syndrome; CS-E, Cushing’s syndrome excluded; CT, controls; Dexa, dexamethasone; Dexa-CRH test, dexamethasone-suppressed corticotropin-releasing hormone test; EAS, ectopic ACTH
Collaborating Center for the WHO Family of International Classifications in China, Beijing, China
Search for other papers by Jingya Zhou in
Google Scholar
PubMed
Collaborating Center for the WHO Family of International Classifications in China, Beijing, China
Search for other papers by Meng Zhang in
Google Scholar
PubMed
Key Laboratory of Endocrinology of National Health Commission of People’s Republic of China, Beijing, China
Search for other papers by Lin Lu in
Google Scholar
PubMed
China Pituitary Disease Registry Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Search for other papers by Xiaopeng Guo in
Google Scholar
PubMed
China Pituitary Disease Registry Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Search for other papers by Lu Gao in
Google Scholar
PubMed
Search for other papers by Weigang Yan in
Google Scholar
PubMed
Clinical Epidemiology Unit, International Epidemiology Network, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Search for other papers by Haiyu Pang in
Google Scholar
PubMed
Collaborating Center for the WHO Family of International Classifications in China, Beijing, China
Search for other papers by Yi Wang in
Google Scholar
PubMed
China Pituitary Disease Registry Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Search for other papers by Bing Xing in
Google Scholar
PubMed
(ACTH)-dependent and ACTH-independent etiologies. The former includes Cushing’s disease (CD) and ectopic ACTH syndrome (EAS), and the latter includes adrenocortical adenoma (ACA), adrenocortical carcinoma (ACC), primary bilateral macronodular adrenal
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by David A Cano in
Google Scholar
PubMed
Search for other papers by Eva Venegas-Moreno in
Google Scholar
PubMed
Search for other papers by Patrick Petrossians in
Google Scholar
PubMed
Search for other papers by Elena Dios in
Google Scholar
PubMed
Search for other papers by Emilie Castermans in
Google Scholar
PubMed
Search for other papers by Alvaro Flores-Martínez in
Google Scholar
PubMed
Search for other papers by Vincent Bours in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
Search for other papers by Alfonso Soto-Moreno in
Google Scholar
PubMed
Introduction Clinically apparent pituitary adenomas are present in about 1:1000 of the general population in Europe; the most frequent sub-types are prolactinomas, non-secreting adenomas and somatotropinomas, while Cushing’s disease and
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Search for other papers by Angelica Sharma in
Google Scholar
PubMed
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Search for other papers by Katharine Lazarus in
Google Scholar
PubMed
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Search for other papers by Deborah Papadopoulou in
Google Scholar
PubMed
Search for other papers by Hemanth Prabhudev in
Google Scholar
PubMed
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Department of Clinical Biochemistry, North West London Pathology, London, UK
Search for other papers by Tricia Tan in
Google Scholar
PubMed
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Search for other papers by Karim Meeran in
Google Scholar
PubMed
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Department of Clinical Biochemistry, North West London Pathology, London, UK
Search for other papers by Sirazum Choudhury in
Google Scholar
PubMed
summarised in Table 2 . Table 2 Causes of secondary adrenal insufficiency. Cause of secondary adrenal insufficiency Patient population ( n = 48) Pathology requiring trans-sphenoidal pituitary surgery Cushing’s disease
Search for other papers by Patricia Arroyo Tardio in
Google Scholar
PubMed
Search for other papers by Gabriela Baldini in
Google Scholar
PubMed
University Clinic of Medicine, Cantonal Hospital Baselland, Liestal, Switzerland
Search for other papers by Eleonora Seelig in
Google Scholar
PubMed
cortisol response to food is essential as amplified or recurrent cortisol surges could lead to hypercortisolism and contribute to obesity. The consequences of hypercortisolism on weight are evident in patients with Cushing’s disease who have excessive
Department of Research and Development, Region Kronoberg, Växjö, Sweden
Search for other papers by Eva Olga Melin in
Google Scholar
PubMed
Search for other papers by Magnus Hillman in
Google Scholar
PubMed
Department of Endocrinology, Skane University Hospital, Lund, Sweden
Search for other papers by Mona Landin-Olsson in
Google Scholar
PubMed
their normal environment ( 31 ). Third, the cut-off level we chose to indicate high MSC has clinical implications. In previous research this cut-off level for high MSC was highly predictive of Cushing’s disease in patients with clinical features of
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by Liliya Rostomyan in
Google Scholar
PubMed
Search for other papers by Daniela Betea in
Google Scholar
PubMed
Search for other papers by Jean-François Bonneville in
Google Scholar
PubMed
Department of Pathological Cytology and Anatomy, Foch Hospital, Paris, France
Search for other papers by Chiara Villa in
Google Scholar
PubMed
Search for other papers by Natalia S Pellegata in
Google Scholar
PubMed
Search for other papers by Beatrice Waser in
Google Scholar
PubMed
Search for other papers by Jean-Claude Reubi in
Google Scholar
PubMed
Search for other papers by Catherine Waeber Stephan in
Google Scholar
PubMed
Search for other papers by Emanuel Christ in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
preferentially to SST5 and SST2 ( 20 ). In the clinical setting, pasireotide is used in either short-acting or long-acting depot formulations for the treatment of Cushing’s disease and acromegaly ( 21 , 22 ). In acromegaly, pasireotide LAR is indicated for
Department of Neuroscience DNS, University of Padova, Padova, Italy
Search for other papers by Filippo Ceccato in
Google Scholar
PubMed
Nuclear Medicine Unit, Department of Medicine – DIMED, University-Hospital of Padova, Padova, Italy
Padova Neuroscience Center PNC, University of Padova, Padova, Italy
Search for other papers by Diego Cecchin in
Google Scholar
PubMed
Search for other papers by Michele Gregianin in
Google Scholar
PubMed
Search for other papers by Giacomo Ricci in
Google Scholar
PubMed
Department of Mathematics ‘Tullio Levi-Civita’ DM, University of Padova, Padova, Italy
Search for other papers by Cristina Campi in
Google Scholar
PubMed
Search for other papers by Filippo Crimì in
Google Scholar
PubMed
Search for other papers by Marta Bergamo in
Google Scholar
PubMed
Search for other papers by Annibale Versari in
Google Scholar
PubMed
Search for other papers by Carmelo Lacognata in
Google Scholar
PubMed
Search for other papers by Federico Rea in
Google Scholar
PubMed
Search for other papers by Mattia Barbot in
Google Scholar
PubMed
Search for other papers by Carla Scaroni in
Google Scholar
PubMed
Introduction Cushing’s syndrome (CS), characterized by excessive endogenous cortisol secretion, is in most cases ACTH-dependent. Corticotropin (ACTH) secretion arises from a pituitary adenoma (Cushing’s disease) or, less frequently, from a non
Search for other papers by M Cherenko in
Google Scholar
PubMed
Search for other papers by N M Appelman-Dijkstra in
Google Scholar
PubMed
Search for other papers by A L Priego Zurita in
Google Scholar
PubMed
Search for other papers by N R Biermasz in
Google Scholar
PubMed
Search for other papers by O M Dekkers in
Google Scholar
PubMed
Search for other papers by F A Klok in
Google Scholar
PubMed
Search for other papers by N Reisch in
Google Scholar
PubMed
Search for other papers by A Aulinas in
Google Scholar
PubMed
Search for other papers by B Biagetti in
Google Scholar
PubMed
Search for other papers by S Cannavo in
Google Scholar
PubMed
Search for other papers by L Canu in
Google Scholar
PubMed
Search for other papers by M Detomas in
Google Scholar
PubMed
Search for other papers by F Devuyst in
Google Scholar
PubMed
Search for other papers by H Falhammar in
Google Scholar
PubMed
Search for other papers by R A Feelders in
Google Scholar
PubMed
Search for other papers by F Ferrau in
Google Scholar
PubMed
Search for other papers by F Gatto in
Google Scholar
PubMed
Search for other papers by C Grasselli in
Google Scholar
PubMed
Search for other papers by P van Houten in
Google Scholar
PubMed
Search for other papers by C Hoybye in
Google Scholar
PubMed
Search for other papers by A M Isidori in
Google Scholar
PubMed
Search for other papers by A Kyrilli in
Google Scholar
PubMed
Search for other papers by P Loli in
Google Scholar
PubMed
Search for other papers by D Maiter in
Google Scholar
PubMed
Search for other papers by E Nowak in
Google Scholar
PubMed
Search for other papers by R Pivonello in
Google Scholar
PubMed
Search for other papers by O Ragnarsson in
Google Scholar
PubMed
Search for other papers by R V Steenaard in
Google Scholar
PubMed
Search for other papers by N Unger in
Google Scholar
PubMed
Search for other papers by A van de Ven in
Google Scholar
PubMed
Search for other papers by S M Webb in
Google Scholar
PubMed
Search for other papers by D Yeste in
Google Scholar
PubMed
University of Glasgow, Office for Rare Conditions, Glasgow, UK
University of Glasgow, Developmental Endocrinology Research Group, Royal Hospital for Children, Glasgow, UK
Search for other papers by S F Ahmed in
Google Scholar
PubMed
Search for other papers by A M Pereira in
Google Scholar
PubMed
%) 41 (59.4%) 10 (83.3%) 154 (69.3%) Surgery: n (%) 133 (94.3%) 64 (92.8%) 7 (58.3%) 204 (91.9%) CSI, Cushing severity index; VTE, venous thromboembolism. One hundred forty-one patients had Cushing’s disease (64
Search for other papers by Peter Wolf in
Google Scholar
PubMed
Search for other papers by Yvonne Winhofer in
Google Scholar
PubMed
High Field MR Centre, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
Search for other papers by Martin Krššák in
Google Scholar
PubMed
Search for other papers by Michael Krebs in
Google Scholar
PubMed
metabolic comorbidities in Cushing’s disease including dyslipidemia and the high prevalence of T2DM, it is tempting to speculate about glucolipotoxic effects on the heart, although no data on ectopic lipid accumulation in the heart in endogenous